Physician profile
Inderpal Singh
NPI 1669097952
$2,371.67
in general payments reported to CMS, 2019-2025
11 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $118 · 2024: $921 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.36 |
| Education | $237.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $579.48 | 2022-2025 | Lifevest |
| Stryker Corporation | $488.83 | 2021 | |
| Abbott Laboratories | $428.35 | 2024-2025 | Ensite, Perclose Prostyle, Aveir |
| Boston Scientific Corporation | $195.98 | 2022-2025 | General - Atherectomy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.78 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $149.04 | 2024 | Wainua |
| Abiomed | $130.54 | 2024 | Impella |
| Kestra Medical Technology Services, INC. | $118.67 | 2025 | Assure Wcd |
| Shockwave Medical, INC | $76.65 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $28.84 | 2024 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $20.51 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderpal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.